Adaptive Biotechnologies (FRA:1HM) Equivalent Admissions #: 0.00 (As of . 20)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:1HM Adaptive Biotechnologies Corp FRA:1HM
68 GF Score
Price €20.00
GF Value €9.07
Valuation Significantly Overvalued
! 5 Warning Signs
View Full Analysis

What is Adaptive Biotechnologies Equivalent Admissions #?

Adaptive Biotechnologies FRA:1HM +8.28% 68 Equivalent Admissions # is 0.00 as of . 20. GuruFocus rates FRA:1HM with a GF Score™ of 68/100 and a GF Value™ of €9.07 (Significantly Overvalued). The stock has 5 warning signs investors should review.

Equivalent Admissions # are a general measure used to indicate combined inpatient and outpatient volumes.

The historical rank and industry rank for Adaptive Biotechnologies's Equivalent Admissions # or its related term are showing as below:

FRA:1HM's Equivalent Admissions # is not ranked *
in the Medical Diagnostics & Research industry.
Industry Median:
* Ranked among companies with meaningful Equivalent Admissions # only.

Adaptive Biotechnologies Equivalent Admissions # Historical Data

* Premium members only.

The historical data trend for Adaptive Biotechnologies's Equivalent Admissions # can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Adaptive Biotechnologies Equivalent Admissions # Chart


FRA:1HM
68GF Score
Adaptive Biotechnologies Corp FRA:1HM
Equivalent Admissions # is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions
What does a Equivalent Admissions # of 0.00 mean?
Adaptive Biotechnologies (FRA:1HM) has a Equivalent Admissions # of 0.00 as of . 20. Equivalent Admissions are a general measure used to indicate combined inpatient and outpatient volumes. View historical data on Adaptive Biotechnologies and its competitors.
Is Adaptive Biotechnologies' Equivalent Admissions # too high?
Adaptive Biotechnologies' current Equivalent Admissions # is 0.00. Overall, Adaptive Biotechnologies has a GF Score™ of 68/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Adaptive Biotechnologies' Equivalent Admissions # compare to GRAL and WGS?
Adaptive Biotechnologies' Equivalent Admissions # of 0.00 can be compared against companies in the Medical Diagnostics & Research industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Equivalent Admissions # for a Medical Diagnostics & Research company?
A good Equivalent Admissions # depends on the Medical Diagnostics & Research industry context. However, Equivalent Admissions # should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Equivalent Admissions # mean?
A high Equivalent Admissions # can signal that a stock is expensive relative to its fundamentals. Equivalent Admissions are a general measure used to indicate combined inpatient and outpatient volumes. View historical data on Adaptive Biotechnologies and its competitors. Adaptive Biotechnologies's current Equivalent Admissions # is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Adaptive Biotechnologies stock overvalued right now?
Based on GuruFocus' analysis, Adaptive Biotechnologies (FRA:1HM) is currently considered Significantly Overvalued. The stock's GF Value™ is €9.07, compared to a current price of €20.00 — trading 120.5% above its estimated fair value. The current Equivalent Admissions # is 0.00. Adaptive Biotechnologies' overall GF Score™ is 68/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Equivalent Admissions # calculated?
Equivalent Admissions # is calculated from a company's financial statements. For Adaptive Biotechnologies (FRA:1HM), the current Equivalent Admissions # is 0.00 as of . 20. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Adaptive Biotechnologies (FRA:1HM) Overvalued in 2026?

Based on GuruFocus' analysis, Adaptive Biotechnologies stock appears to be overvalued. The current stock price of €20.00 is trading 120.5% above its estimated GF Value™ of €9.07. GuruFocus considers Adaptive Biotechnologies to be Significantly Overvalued.

Key valuation signals for FRA:1HM:

  • Equivalent Admissions #: 0.00
  • GF Value™: €9.07 vs. price of €20.00 (120.5% above fair value)
  • GF Score™: 68/100 with 5 warning signs

No single metric tells the full story. See the FRA:1HM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Adaptive Biotechnologies Business Description

Other Exchanges ADPT:USA
Address 1165 Eastlake Avenue East, Seattle, WA, USA, 98109
Adaptive Biotechnologies Corp is a company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is a test authorized by the FDA for the detection and monitoring of minimal residual disease (MRD) in patients with multiple myeloma (MM), B cell acute lymphoblastic leukemia (ALL) and chronic lymphocytic leukemia (CLL) and is also available as a CLIA-validated laboratory developed test (LDT) for patients with other lymphoid cancers. The company has two operating segments: Minimal Residual Disease and Immune Medicine. The company generates the majority of its revenue from the Minimal Residual Disease segment.
68GF Score

Get the complete analysis for FRA:1HM

Equivalent Admissions # is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€20.00
Price
€9.07
GF Value